Thomas Heard 10/732,900

[redacted]

```
(FILE 'CAPLUS' ENTERED AT 14:40:34 ON 21 APR 2005)
          DEL HIS Y

FILE 'REGISTRY' ENTERED AT 14:47:52 ON 21 APR 2005
          ACT HEARD2/A
          ---------
L1             STR
L2          87 SEA FILE=REGISTRY SSS FUL L1
          ---------
L3           0 S L2 NOT (CAPLUS OR CA OR USPATFULL)/LC

FILE 'CAPLUS' ENTERED AT 14:48:14 ON 21 APR 2005
L4           2 S L2
```


04/21/2005 Searched by Alex Waclawiw

=> fil reg
FILE 'REGISTRY' ENTERED AT 14:49:29 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

=> d que stea l2
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE
L2 37 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 209 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.01

=> d his l3

(FILE 'REGISTRY' ENTERED AT 14:47:52 ON 21 APR 2005)

L3 0 S L2 NOT (CAPLUS OR CA OR USPATFULL)/LC

=> fil caplus
FILE 'CAPLUS' ENTERED AT 14:49:38 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17
FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos 14
L1 STR
L2 87 SEA FILE=REGISTRY SSS FUL L1
L4 2 SEA FILE=CAPLUS ABB=ON PLU=ON L2

=> d .ca 1

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:603180 CAPLUS
DOCUMENT NUMBER: 141:270992
TITLE: DNA Binding Ligands with Improved in Vitro and in Vivo Potency against Drug-Resistant Staphylococcus aureus
AUTHOR(S): Hu, Wenhao; Buerli, Roland W.; Kaizerman, Jacob A.; Johnson, Kirk W.; Gross, Matthew I.; Iwamoto, Mari; Jones, Peter; Lofland, Denene; Difuntorum, Stacey; Chen, Hsiu; Bozdogan, Buelent; Appelbaum, Peter C.; Moser, Heinz E.
CORPORATE SOURCE: Genesoft Pharmaceuticals Inc., South San Francisco, CA, 94080, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(18), 4352-4355
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 29 Jul 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Potent in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA) has been difficult to achieve with previously reported DNA binding antibacterials. Herein, we describe an efficient access to a focused library of new analogs yielding compds. with improved activity in a mouse peritonitis model. The most potent mols. (I and II) exhibit efficacy against MRSA at ED50 values of .apprx.1 and .apprx.5 mg/kg, resp., and display excellent in vitro activity against vancomycin-resistant S. aureus.
CC 1-3 (Pharmacology)
Section cross-reference(s): 10, 28
IT 478492-67-0P 478492-74-9P **711020-87-0P 711020-96-1P 711020-97-2P 711020-99-4P 711021-04-4P**